CervoMed reports Phase 2a biomarker data for neflamapimod in DLB; RewinD-LB topline due Dec 2024

CervoMed Inc.

Plasma GFAP significantly reduced by neflamapimod (p=0.015 vs placebo); reductions linked to clinical improvement.
RewinD-LB Phase 2b trial fully enrolled; topline data expected December 2024.
Study has >95% statistical power for primary endpoint (CDR-SB) after excluding patients with tau pathology.
DLB affects >1.4M patients in U.S. and EU with no approved treatment, per CervoMed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.